This paper is primarily concerned with estimating an upper bound for the contribution of technological progress on health care costs as motivated by the recent debate on U.S. health care reform. We critically address whether technology is at least 50% of the increase in health care costs as...

This paper estimates a duration model of late stage drug development in the pharmaceutical industry using publicly available data. The paper presents descriptive results on the estimated relationship between a particular drug's characteristics such as therapy category, route of administration...